Skip to content

Application of nadroparin calcium in hemoperfusion: a randomzied controlled trial.

Application of nadroparin calcium in hemoperfusion

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034074
Enrollment
Unknown
Registered
2020-06-22
Start date
2020-07-01
Completion date
Unknown
Last updated
2020-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases requiring hemoperfusion

Interventions

Heparin group:Anticoagulation with heparin for hemoperfusion
Naltrexaparin calcium group:Anticoagulation and hemoperfusion with naltrexaparin calcium
Low molecular weight heparin calcium group:Anticoagulation and hemoperfusion with low molecular weight heparin calcium

Sponsors

Nantong University Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The patients in our department with signs of hemoperfusion; 2. Patients aged over 18 years; 3. Patients who sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant women and pregnant patients; 2. Patients with rheumatic immune system disease, blood system disease, tumor, coronary heart disease, pulmonary embolism and other diseases that affect blood coagulation; 3. Patients with severe hepatorenal insufficiency and contraindications of anticoagulation; 4. Patients with severe mental disorders and drug dependence.

Design outcomes

Primary

MeasureTime frame
platelet;

Secondary

MeasureTime frame
Thromboelastogram;hemoglobin;Platelet surface glycoprotein;

Countries

China

Contacts

Public ContactYanbo Shen

Nantong University Affiliated Hospital

bennet7200@163.com+86 13862955296

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026